Ocugen Inc
NASDAQ:OCGN

Watchlist Manager
Ocugen Inc Logo
Ocugen Inc
NASDAQ:OCGN
Watchlist
Price: 0.9074 USD 0.72% Market Closed
Market Cap: 261.2m USD
Have any thoughts about
Ocugen Inc?
Write Note

Ocugen Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ocugen Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Ocugen Inc
NASDAQ:OCGN
Long-Term Debt
$1.6m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Debt
$58.5B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Debt
$56.9B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Debt
$114m
CAGR 3-Years
-39%
CAGR 5-Years
-27%
CAGR 10-Years
-18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Debt
$2.7B
CAGR 3-Years
11%
CAGR 5-Years
31%
CAGR 10-Years
17%
No Stocks Found

Ocugen Inc
Glance View

Market Cap
261.2m USD
Industry
Biotechnology

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

OCGN Intrinsic Value
0.2889 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Ocugen Inc's Long-Term Debt?
Long-Term Debt
1.6m USD

Based on the financial report for Jun 30, 2024, Ocugen Inc's Long-Term Debt amounts to 1.6m USD.

What is Ocugen Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-3%

Over the last year, the Long-Term Debt growth was 3%. The average annual Long-Term Debt growth rates for Ocugen Inc have been -3% over the past three years .

Back to Top